Claims
- 1. A compound of the formula: where:X1 and X2 are independently selected from —F, —Cl, —Br, and —OSO2R1; Y1 and Y2 are independently selected from —CN, —NO2, —COR1, —CONR1R2, —SO2R1, and —SO2R1R2; and each R1 is independently selected from optionally substituted alkyl, optionally substituted aryl, and optionally substituted aralkyl; each R2 is independently selected from H, optionally substituted alkyl, optionally substituted aryl, and optionally substituted aralkyl, or a pharmaceutically acceptable salt thereof.
- 2. A compound of claim 1, where X1 and X2 are the same.
- 3. A compound of claim 1, where Y1 and Y2 are the same.
- 4. A compound of claim 1, where X1 and X2 are independently selected from —F and —Cl.
- 5. A compound of claim 1, where Y1 and Y2 are independently selected from —CN, —NO2, and —COR1.
- 6. The compound of claim 1 which is 1,3-bis(4-chloro-3-nitrophenyl)urea.
- 7. A pharmaceutical composition comprising:a compound of claim 1, and a pharmaceutically acceptable excipient.
- 8. A pharmaceutical composition comprising:a compound of claim 2, and a pharmaceutically acceptable excipient.
- 9. A pharmaceutical composition comprising:a compound of claim 3, and a pharmaceutically acceptable excipient.
- 10. A pharmaceutical composition comprising:a compound of claim 4, and a pharmaceutically acceptable excipient.
- 11. A pharmaceutical composition comprising:a compound of claim 5, and a pharmaceutically acceptable excipient.
- 12. A pharmaceutical composition comprising:a compound of claim 6, and a pharmaceutically acceptable excipient.
- 13. A method of treating a disease in a mammal treatable by administration of a stimulator of Fas-mediated apoptosis, comprising:administering to the mammal a therapeutically effective amount of a compound of claim 1.
- 14. The method of claim 13, where the disease is selected from the group consisting of autoimmune diseases, infectious diseases, and malignancies.
- 15. The method of claim 14, further comprising treating said mammal with a conventional form of therapy for the disease.
- 16. The method of claim 15, where the conventional form-of therapy comprises administering a drug selected from the group consisting of immunosuppressants, antiinflammatory agents, antiviral agents, antibacterial agents, antifungal agents, and anticancer chemotherapeutic agents.
- 17. A method of stimulating Fas-mediated apoptosis in a cell with a Fas receptor, comprising contacting the cell with a compound of claim 1 in an amount sufficient to stimulate the Fas receptor.
- 18. A process for identifying a compound that has at least one function selected from the group of stimulating the Fas receptor and stimulating Fas-mediated apoptosis, the process comprising administering to an assay of Fas binding or of Fas-mediated apoptosis a compound of claim 1 and noting a first result, administering a test compound to the assay and noting a second result, and comparing the first and second results, whereby a test compound producing results similar to or better than the first result is identified as a compound having the desired function.
- 19. A process for identifying a target compound that mimics the function of a compound of claim 1 in an assay, the process comprising administering a compound of claim 1 to the assay and noting a first result, administering a test compound to the assay and noting a second result, and comparing the first and second results, whereby a test compound producing results similar to or better than the first result is identified as a target compound that mimics the function of a compound of claim 1.
- 20. A process for validating, optimizing, or standardizing a bioassay, the process comprising submitting a compound of claim 1 to the bioassay; and validating, optimizing, or standardizing the bioassay by the activity of the compound in the bioassay.
CROSS-REFERENCE TO RELATED APPLICATION
This application claims the priority under 35 USC 119(e) of U.S. Provisional Application No. 60/273,938, filed Mar. 7, 2001, which is incorporated into this application by reference.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4608205 |
Conrow et al. |
Aug 1986 |
A |
Foreign Referenced Citations (2)
Number |
Date |
Country |
9850346 |
Nov 1998 |
WO |
9932463 |
Jul 1999 |
WO |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/273938 |
Mar 2001 |
US |